Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG


Millennium Nucleus on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas and Departamento de Reumatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile; The Lewis M. Farad Department of Pediatrics, Jacobi Medical Center, Bronx, NY 10461; Departments of Pediatrics and Pathology and Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461; and Departamento de Ciencias Biológicas, Laboratorio de Biología Celular y Farmacología, Universidad Andrés Bello, Santiago 8370146, Chile

Respiratory syncytial virus (RSV) is one of the leading causes of childhood hospitalization and a major health burden worldwide. Unfortunately, because of an inefficient immunological memory, RSV infection provides limited immune protection against reinfection. Furthermore, RSV can induce an inadequate Th2-type immune response that causes severe respiratory tract inflammation and obstruction. It is thought that effective RSV clearance requires the induction of balanced Th1-type immunity, involving the activation of IFN-γ-secreting cytotoxic T cells. A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette–Guerin (BCG), which has been used in newborns for decades in several countries as a tuberculosis vaccine. Here, we show that immunization with recombinant BCG strains expressing RSV antigens promotes protective Th1-type immunity against RSV in mice. Activation of RSV-specific T cells producing IFN-γ and IL-2 was efficiently obtained after immunization with recombinant BCG. This type of T cell immunity was protective against RSV challenge and caused a significant reduction of inflammatory cell infiltration in the airways. Furthermore, mice immunized with recombinant BCG showed no weight loss and reduced lung viral loads. These data strongly support recombinant BCG as an efficient vaccine against RSV because of its capacity to promote protective Th1 immunity.

Th1 cell response | RSV | Immunopathology | T cell immunity

Respiratory syncytial virus (RSV) is an enveloped, negative, single-stranded RNA virus belonging to the Paramyxoviridae family with a genome that encodes for 11 proteins (1). This virus is the leading cause of viral bronchiolitis and pneumonia worldwide, infecting more than 70% of children in the first year of life and nearly 100% of children by age 2 years (2). Despite being highly infectious, RSV does not induce an effective immunological memory, and repeated infections are therefore very frequent (3, 4). Although symptoms associated with RSV infection usually manifest as rhinitis in adults, in premature infants, the elderly, and immunosuppressed individuals, RSV infection frequently leads to severe symptoms and airway obstruction (5, 6). Furthermore, it has been proposed that exposure to RSV infection early in life can lead to increased susceptibility to recurrent allergic wheezing and asthma during the following years (7). Considering epidemiological data, RSV is responsible for a health problem that is extremely expensive for individuals, governments, and health care systems. Unfortunately, to date there are no commercially available vaccines against this pathogen. Vaccine trials for RSV were first carried out with a formalin-inactivated RSV formulation (FI-RSV) in the mid-1960s (8). However, vaccinated children experienced exacerbated pulmonary disease and required hospitalization upon subsequent RSV infection, whereas nonvaccinated control children experienced significantly milder symptoms (8, 9). The failure of FI-RSV remained unexplained for at least 2 decades, primarily because of the poor understanding of the immune responses triggered by RSV infection. However, recent studies have suggested that the FI-RSV vaccine failed because of the fact that it promoted an allergic-like Th2 immune response against the virus (10–12). This particular Th2-type response is characterized by the activation and proliferation of CD4+ T cells that secrete a pattern of cytokines that promote increased and accelerated infiltration of eosinophils and neutrophils into the lung tissues. Furthermore, this allergic-like cellular environment dampens CD8+ cytotoxic T cell activation and effector functions, such as the secretion of IFN-γ (13). As a result, clearance of RSV is delayed, lung damage is induced, and virus dissemination is promoted.

Over the last few years, several experimental approaches aimed at developing an effective vaccine against RSV have been designed and assessed, such as attenuated RSV particles (14), recombinant viruses (different from RSV) that express RSV antigens (15–17), purified RSV proteins administered with bacterial adjuvants (17, 18), RSV proteins packed as immune stimulating complexes (19), and RSV sequence peptides applied together with adjuvants (20). Although several RSV vaccine candidates may currently be at the end of their corresponding clinical trials around the world, most of these approaches unfortunately promise to be expensive to the point of being unaffordable for middle/low socioeconomic groups. Alternatively, the use of recombinant bacteria for RSV antigens as candidate vaccines against this virus has not been evaluated. Mycobacterium bovis bacillus Calmette–Guerin (BCG) is currently used worldwide as a vaccine against tuberculosis and has been used by more than 1 billion humans since its introduction in 1921. In both adults and newborns, BCG induces cell-mediated immune responses and Th1 cytokines that persist for at least 1 year after vaccination (21–23). Because of the fact that BCG vaccination has been shown to be safe in newborns, infants, and adults, this bacterium arises as an attractive vaccine vector candidate for recombinant antigens. Indeed, several studies have shown that recombinant BCG strains efficiently induce Th1 responses against several pathogens and diseases (24–32).

Here, we have evaluated whether BCG strains expressing RSV antigens promote a protective immune response against RSV infection in mice. Our data show that vaccination with recombinant

Edited by Ralph M. Steinman, The Rockefeller University, New York, NY, and approved October 22, 2008 (received for review July 1, 2008)
BCG strains expressing RSV proteins N or M2 induces protective immunity against viral infection. The BCG-based vaccine was able to reduce weight loss, lung viral protein loads, and polymorphonuclear cell infiltration in the airways of RSV-challenged mice. This protective response is consistent with increased secretion of IFN-γ and IL-2 by T cells stimulated in vitro with RSV proteins. In addition, adoptive transfer of T cells obtained from mice vaccinated with recombinant BCG can protect naive mice from RSV challenge. In summary, our results suggest that recombinant BCG expressing RSV antigens can be used as a safe and protective vaccine against virulent RSV by inducing an efficient Th1-polarized, T cell-mediated specific immunity.

**Results**

**Immunization with Recombinant BCG Reduces the Severity of RSV-Induced Disease.** Genes coding for RSV-N and RSV-M2 proteins were cloned into the integrative plasmid pMV361 (24) to produce the recombinant BCG-N and BCG-M2 strains. These antigens were chosen based on their previously reported capacity to induce RSV-specific cytotoxic CD8⁺ T cell responses (33, 34). Here, we tested whether expression of these antigens in BCG could promote protective T cell immunity against RSV.

As shown in Fig. 1, N and M2 proteins were efficiently expressed by both recombinant BCG strains. Quantitative Western blot assay revealed that these recombinant BCG strains expressed ~2.3 ng/10⁶ cfu N protein and 5.7 ng/10⁶ cfu M2 protein (data not shown).

To evaluate whether recombinant BCG strains can protect animals from virulent RSV challenge, 4- to 6-week-old BALB/c mice were immunized with 10⁷ cfu of either BCG-N or BCG-M2 using a single subdermal injection in the dorsal flank. Control groups received PBS-Tween 0.02% (unimmunized), 1 × 10⁷ pfu of UV-inactivated RSV (UV-RSV), 10⁶ cfu of either nonrecombinant BCG (WT-BCG) or ovalbumin-recombinant BCG (BCG-OVA). Twenty-one days after immunization, all animals were challenged with 1 × 10⁶ pfu of virulent RSV, and body weight was determined daily for 4 days after infection. As shown in Fig. 2A, significant weight loss was observed for unimmunized animals or mice immunized either with UV-RSV or WT-BCG, as well as BCG-OVA (data not shown). These data are consistent with previous studies indicating that naive mice challenged with RSV can show significant weight loss as early as 24 h after infection (35–37). In sharp contrast, mice immunized with either BCG-N or BCG-M2 showed no significant weight loss after RSV challenge, similarly to uninfected mice (Fig. 2A). These observations were confirmed when disease severity was evaluated using computerized axial tomography (CAT) scan. Signs of pulmonary inflammation could be observed in unimmunized animals 3 days after RSV challenge as pneumonia foci on CAT scan images [supporting information (SI) Fig. S1 and Movie S1]. In contrast, mice immunized with recombinant BCG expressing RSV antigens showed neither pneumonia foci nor lung inflammation after RSV challenge, and their pulmonary parenchyma was similar to that of uninfected mice (Fig. S1 and Movies S1–S3). These data suggest that vaccination with BCG-N or BCG-M2 can significantly reduce RSV-related disease symptoms.

**Immunization with Recombinant BCG Prevents Recruitment of Inflammatory Cells into the Airways.** Consistent with the data shown above, RSV challenge caused massive infiltration of inflammatory cells into the airways of unimmunized mice, as well as in mice immunized either with WT-BCG, UV-RSV (Fig. 2B), or BCG-OVA (data not shown). Flow cytometry revealed that most infiltrating cells were positive for the surface marker CD11b (Fig. 2C). Because CD11b⁺ positive cells in bronchoalveolar lavages (BALs) were also positive for Ly-6C/Ly-6C marker (GR1) (Fig. 2C Inset), it is likely that most of the infiltrating cells were neutrophils. Cytospin preparation of BAL fluid after RSV challenge confirmed substantial infiltration of neutrophils in the airways of unimmunized mice and mice immunized with WT-BCG or UV-RSV (Fig. 3), as well as mice immunized with BCG-OVA (data not shown). Contrarily, after RSV challenge no significant recruitment of CD11b⁺ cells to the airways was observed for mice immunized either with BCG-N or BCG-M2 recombinant strains (Fig. 2C). In addition, immunization with recombinant BCG strains also prevented RSV-induced neutrophil invasion of BALs (Fig. 3). These results suggest that vaccination with BCG-N or BCG-M2 can significantly reduce the recruitment of inflammatory cells to the airways after RSV infection.

---

**Fig. 1.** Expression of RSV M2 and N proteins by recombinant BCG strains. BCG was electrotansformed with plasmid pMV361-M2 or pMV361-N and selected on solid 7H10 medium supplemented with 20 μg/mL kanamycin. Expression of recombinant RSV proteins was assessed by Western blot analysis using rabbit polyclonal antiserum specific for the M2 or N protein. A total of 25 μg of whole proteins prepared from BCG-M2 or BCG-N was loaded in each gel. As positive controls, recombinant N or M2 proteins and total proteins of RSV-infected HeP-2 cells were loaded. As negative control, proteins prepared from WT-BCG (nonrecombinant) were included.

**Fig. 2.** Immunization with BCG-N and BCG-M2 protects mice against RSV. Groups of BALB/c mice (5 to 6 weeks of age) received subdermal immunization with 1 × 10⁷ cfu of WT-BCG, BCG-M2, BCG-N, or UV-inactivated RSV and infected with 1 × 10⁶ pfu RSV. Uninfected and unimmunized mice were included as control groups. (A) Body weight loss after RSV infection. Weight loss for BCG-M2-immunized and BCG-N-immunized mice was significantly lower than for mice immunized with WT-BCG or UV-RSV and unimmunized mice (***, P < 0.001, Student's t test between unimmunized and BCG-M2 or BCG-N values). (B) Number of cells in BALs 4 days after RSV infection. BAL cells were obtained as described in Methods and counted with a Neubauer chamber (HGB, Germany). Symbols represent individual mice, and horizontal lines represent means. Cell counts in BALs were significantly lower in mice vaccinated with BCG-N and BCG-M2 compared with unimmunized mice (***, P < 0.001, Student's t test between unimmunized and BCG-M2 or BCG-N values; NS, nonsignificant, Student's t test between unimmunized and WT-BCG values). (C) Percentage of CD11b⁺ cells in BAL 4 days after RSV infection. BAL cells were stained with an FITC-labeled anti-CD11b antibody and analyzed by flow cytometry. Symbols represent individual mice, and horizontal lines represent means. CD11b⁺ positive cell counts were significantly lower in mice vaccinated with BCG-N and BCG-M2 compared with unimmunized mice (***, P < 0.001, Student's t test between unimmunized and BCG-N or BCG-M2 values; NS, nonsignificant, Student's t test between unimmunized and WT-BCG values). Inset shows a CD11b/GR1 dot plot for BAL cells from RSV-infected mice.
Immunization with Recombinant BCG Prevents Histopathology and Viral Load in Lungs of RSV-Infected Animals. Five days after RSV challenge, lung tissue from unimmunized or WT-BCG-immunized mice showed an elevated pulmonary histopathology score (HPS, Fig. 4B), as evidenced by significant inflammatory cell infiltration in alveoli and peribronchial tissues (Fig. 4A). Interestingly, mice immunized with UV-RSV and challenged with RSV showed increased lung inflammation, as evidenced by higher infiltration of inflammatory cells in alveoli, bronchioles, and peribroncholar tissues (Fig. 4). Consistent with the massive infiltration of inflammatory cells, increased eosinophilic activity (data not shown) was observed in the lung tissue of unimmunized and UV-RSV-immunized mice. These findings suggest that the pronounced weight loss observed in control mice after RSV infection is related to neutrophil infiltration in the airways and lung inflammation. In contrast, mice immunized with BCG-N or BCG-M2 showed reduced HPS (Fig. 4B), as evidenced by significantly less cellular infiltration in the lungs in response to RSV challenge and lung histology equivalent to uninfected mice (Fig. 4C). Consistently, no significant eosinophil infiltration in lung tissue was observed for mice immunized either with BCG-M2 or BCG-N (Fig. S2).

Immunization with BCG-M2 or BCG-N prevents airway infiltration by neutrophils after RSV infection. (A) Four days after RSV infection, BALs obtained from unimmunized or immunized mice with BCG-M2, BCG-N, WT-BCG, or UV-RSV were spun on glass slides, stained with May-Grünwald and Giemsa, and observed under a light microscope at 40× magnification. As a control, BALs from uninfected mice were included. (B) Graph shows the amount of total cells (gray) and neutrophils (black) per field, as quantified by light microscopy at 40× magnification in at least 6 random fields per sample. Bars represent means ± SE.

Mice Immunized with Recombinant BCG Exhibit RSV-Specific T Cells That Secrete Th1 Cytokines. To evaluate whether humoral or cellular adaptive immunity is induced by BCG-N and BCG-M2, IgG titers specific for N or M2 were determined at 7, 14, and 21 days after immunization. No significant increase in anti-N or anti-M2 IgG serum titers could be observed for any of the groups of immunized animals, compared with the unimmunized controls (data not shown). These data suggest that a T-cell immune response rather than a humoral response might preferentially be induced by immunization with recombinant BCG. To evaluate this notion, cytokine secretion was determined for T cells obtained from spleens 21 days after immunization in response to antigenic stimulation. Cells were restimulated in vitro for 5 days with recombinant N or M2 proteins, and IFN-γ, IL-2, and IL-4 were measured in culture supernatants. As shown in Fig. 6A, spleen cell suspensions obtained from mice immunized with BCG-N secreted considerable amounts of IFN-γ and IL-2 only in response to N protein. Similarly, cell suspensions obtained from mice vaccinated with BCG-M2 secreted significant amounts of IFN-γ and IL-2 only when stimulated with M2 protein. In contrast, IFN-γ and IL-2 were not detected in the supernatant of cells derived from unimmunized mice or mice immunized with UV-RSV and WT-BCG (Fig. S2). Although only a modest increase in IL-4 secretion could be detected for T cells obtained from mice immunized with UV-RSV (Fig. 6A), no significant secretion of any Th2-type cytokines, such as IL-4, IL-10, and IL-5, could be measured for T cells obtained from mice immunized with BCG-M2 or BCG-N (data not shown).

Fig. 4. Immunization with BCG-M2 and BCG-N reduces inflammatory cell infiltration into the lungs after RSV infection. (A) Four days after RSV infection, mouse lungs were removed and fixed with paraformaldehyde, and 5-μm cuts were stained with hematoxylin/eosin. Significant polymorphonuclear cell infiltration can be observed in unimmunized, UV-RSV, and WT-BCG-immunized mice. Photos are representative of 3 to 6 independent experiments. (B) HPS for each group: 0, no cellular infiltration; 1, minimal cellular infiltration; 2, slight cellular infiltration; 3, moderate cellular infiltration; 4, severe cellular infiltration, as described in Methods (NS indicates nonsignificant; ***, P < 0.0036, ****, P < 0.0001, Student’s t tests between uninfected and each individual group).

Presence of viral proteins in lung tissues after RSV challenge was determined by immunohistochemistry and immunofluorescence using an HRP-labeled IgG RSV-specific antisera and a biotin-labeled anti-RSV-F antibody, respectively. As shown in Fig. 5A, positive staining for RSV proteins could be detected in respiratory epithelia of unimmunized, UV-RSV- and WT-BCG-immunized mice. These data suggest that RSV replication takes place in lungs of control mice after viral challenge. On the contrary, RSV proteins could not be detected in the respiratory epithelia of mice immunized with recombinant strains of BCG-N or BCG-M2 (Fig. 5A). These results are consistent with quantitative real-time PCR data showing that viral RNA loads in lungs were reduced significantly only in BCG-N-immunized and BCG-M2-immunized mice, compared with unimmunized, WT-BCG or UV-RSV-immunized mice (Fig. 5B). These observations support the notion that vaccination with BCG-N or BCG-M2 can induce protective immunity in mice, reducing viral loads in lungs and preventing excessive inflammatory cell recruitment after RSV infection.
Intravenously injected into naive BALB/c mice. RSV-induced weight loss (BCG-N-immunized mice protects against RSV. T cells obtained from BALB/c mice 21 days after immunization with BCG-N were stimulated for 3 days with N protein and cytometry, as described in SI Methods. Fluorescence countstaining derives from a Cy3-conjugated anti-von Willebrand factor antibody. Positive staining is observed in lungs of unimmunized, UV-RSV, and WT-BCG-immunized mice. Data shown are representative of 3 to 6 independent experiments.

Total RNA from lungs of control and infected animals were obtained and reverse transcribed to quantify the number of N-RSV copies by real-time PCR. Data are expressed as the number of N-RSV gene copies per 5,000 copies of β-actin gene (**, P < 0.01, 1-way ANOVA).

Immunization with BCG-M2 and BCG-N reduces virus presence in lung tissues after RSV infection. (A) Four days after infection, lungs were removed, fixed with paraformaldehyde, and stained with an HRP-labeled anti-RSV antibody (first and third columns (arrowheads show positive staining)) or with a biotin-labeled anti-F antibody followed by streptavidin-FITC (second and fourth columns), as described in SI Methods. Fluorescence countstaining derives from a Cy3-conjugated anti-von Willebrand factor antibody. Positive staining is observed in lungs of unimmunized, UV-RSV, and WT-BCG-immunized mice. Data shown are representative of 3 to 6 independent experiments.

Total RNA from lungs of control and infected animals were obtained and reverse transcribed to quantify the number of N-RSV copies by real-time PCR. Data are expressed as the number of N-RSV gene copies per 5,000 copies of β-actin gene (**, P < 0.01, 1-way ANOVA).

Discussion

The severe symptoms that RSV infection can cause in infants are responsible for a major public health burden and have an extremely high socioeconomic impact worldwide. Research efforts are needed to promote the design of safe, effective, and affordable vaccines capable of protecting against infection caused by RSV. This goal has turned out to be difficult, in part due to the virulence factors displayed by RSV, as well as the immunological component of the pathogenesis induced by this virus (38, 39). Several independent studies have shown that RSV can modulate the host immune response in at least 2 different ways. First, RSV seems to block the activation, expansion, and function of cytotoxic and memory T cells

Immunization with BCG-M2 and BCG-N induces the secretion of Th1-type cytokines and promotes activation of antigen-specific T cells in the spleen. BALB/c mice were immunized with either 100 μL of PBS-Tween 0.02%, 1 × 10^8 cfu of WT-BCG, BCG-M2, BCG-N, or with 1 × 10^7 pfu of UV-inactivated RSV. After 21 days of vaccination, spleen cells were recovered and stimulated with 10 μg/mL of either M2 or N proteins for 5 days to evaluate cytokine secretion. (A) IFN-γ, IL-2, and IL-4 secretion was detected in supernatants of cell suspensions, by ELISA. Spleen cells derived from BCG-M2 or BCG-N secreted significant amounts of IFN-γ and IL-2 after stimulation with their cognate proteins (***, P < 0.0002; **, P < 0.02, Student's t test). Secretion of IL-4 was only observed in spleen cells of mice immunized with UV-RSV (**, P < 0.02, Student’s t test). (B) CD69 expression on the surface of T cells after stimulation with M2 and N protein. Spleen cell suspensions were stimulated with 10 μg/mL N or M2 proteins or left untreated for 72 h, stained with PE anti-CD69, FITC anti-CD8a, and allophycocyanin (APC) anti-CD4 antibodies, and analyzed by flow cytometry, as described in SI Methods. Representative histograms derived from 3 independent experiments show profiles of CD69 expression by CD4+ or CD8+ cells. Numbers in each histogram are the percentages of CD69+ populations positive for CD69. (C) Intracellular IFN-γ production by T cells from BCG-M2-immunized or BCG-N-immunized mice. Representative dot plots of CD4+IFN-γ+ cells (CD69 gated) and a graph summarizing percentages of CD4+/CD69+/IFN-γ+ T cells (means ± SE). White bars are cell stimulated with PBS and gray bars are cells stimulated with N or M2 recombinant proteins, respectively. (D) Transfer of T cells from BCG-N-immunized mice protects against RSV. T cells obtained from BALB/c mice 21 days after immunization with BCG-N were stimulated for 3 days with N protein and intravenously injected into naive BALB/c mice. RSV-induced weight loss (Left) and BAL infiltration by CD11b+ cells (Right) in BALB/c transferred either with CD4+ or CD8+ or both T cell subsets. Nontransferred (NT) and uninfected (UI) mice were included as controls. Data shown are means ± SE from 3 independent experiments. **, P < 0.01; ***, P < 0.001 between nontransferred and transferred mice, Student's t test. NS indicates nonsignificant.
specific to viral antigens. As a result, primary infection does not confer immune protection against subsequent reinfections with antigenically similar RSV strains (40–42). Another example of immune modulation is observed after RSV infection and/or vaccination with inactivated virus, which can induce a detrimental Th2 immune memory. This type of immune response can promote airway inflammation, leading to lung injury after a second exposure to RSV (11, 43). Because of the complexity of the detrimental immune response induced by RSV, more than 2 decades of research have been required to identify a potentially successful approach to generate a safe and protective vaccine against this pathogen. It has been suggested that protection against RSV could be achieved by means of immunization methods capable of promoting a balanced, RSV-specific, Th1-type immune response, which could clear viral infection without excessive or damaging inflammation of the infected tissues. Because several genetically modified RSV strains have failed to promote protective immunity even in the presence of Th1-type cytokines (7), it would seem likely that the choice of vector expressing RSV antigens is a critical parameter for conferring immune protection against the virus.

In this study we demonstrate that vaccination with recombinant BCG strains expressing RSV antigens can dampen RSV-induced disease. Moreover, recombinant BCG strains expressing RSV antigens efficiently promote protective Th1-like immunity, which offers protection against this virus, which fosters clearance of this pathogen with no evident inflammation and lung injury. Interestingly, it is likely that this feature is a consequence related directly to BCG and its capacity to promote a balanced Th1 immune response. It is thought that the capacity of BCG to induce Th1-skewed immune responses would be in part mediated by the cell wall lypomannan and lipoarabinomannan, which promote IL-12 secretion by dendritic cells (44). It seems that this feature of BCG is fundamental for inducing a protective immune response against RSV, because vaccination with other bacterial vectors expressing the same RSV antigens, such as attenuated strains of Salmonella, failed to confer protection against the virus (Fig. S4).

BCG has been applied for several decades as a vaccine against tuberculosis (45) and, more recently, was used successfully as a carrier to promote a Th1 immune response against antigens from other bacterial and viral pathogens, such as measles (24), Borrelia (46, 47), Mycobacterium tuberculosis (48, 49), and Pneumocystis jirovecii (50). In this study we show that recombinant BCG strains expressing either protein N or protein M2 from RSV can promote a cell-mediated, Th1-like, RSV-specific immune response. Our data show that vaccination with these recombinant BCG strains promotes secretion of IFN-γ and IL-2 by RSV-specific T cells residing in spleens of vaccinated mice. As a result, weight loss and recruitment of inflammatory cells to the airways, a process induced by RSV infection, were prevented with the RSV-specific immune response induced by recombinant BCG strains. Furthermore, immunization with BCG expressing RSV proteins significantly reduced virus presence in infected lung tissue after challenge and prevented excessive lung inflammation. On the contrary, unimmunized, WT-BCG-immunized, or UV-RSV-immunized animals showed significant weight loss and inflammatory infiltration into the airways. According to previous studies, RSV-immunized mice showed enhanced inflammatory infiltration within airways and lungs compared with unimmunized animals because of the adverse Th2 immune response promoted by RSV antigens (10). It is noteworthy that after RSV infection, mice immunized with WT-BCG showed a moderate reduction in the amount of inflammatory cells infiltrating the airways. However, differences observed were not statistically significant when compared to unimmunized animals (Fig. 2). This finding is consistent with previous studies showing that BCG immunization can promote IFN-γ secretion by T cells after unspecific stimulation, and reduce allergic responses to inhaled antigens (51, 52). In addition, it has been demonstrated that immunization of newborns with BCG induces a strong Th1 immune response, despite the fact that newborns are prone to Th2 responses upon antigenic challenge (23, 53). Further, several epidemiological studies have provided evidence supporting the notion that Mycobacterium exposure can prevent atopic disorders in humans (54, 55). Nevertheless, the observation that significant weight loss followed RSV infection in mice immunized with WT-BCG would indicate that the unspecific immunity induced by BCG is not sufficient to prevent RSV-induced disease (Fig. 2A). On the contrary, our data suggest that protection against RSV requires specific T cell-mediated immunity involving CD4+ and CD8+ T cells secreting Th1-type cytokines (Fig. 6D). This notion is further supported by the observation that BCG strains expressing RSV antigens failed to confer protection to RSV in RAG-deficient mice (Fig. S3).

It is likely that pathogen-associated molecular patterns derived from recombinant BCG can modify the nature of adaptive immunity to RSV antigens by promoting a Th1-like T cell response, which can counteract the allergic-like immune response triggered by natural RSV infection. Our results support the notion that vaccination with BCG expressing RSV antigens induces a Th1 immune response, which protects against RSV infection. Considering that administration of BCG to newborns has been demonstrated to be safe, strains of BCG expressing RSV antigens are candidates for a potential new vaccine that could be administered to young children to prevent disease induced by RSV infection during infancy.

### Methods

#### Mouse and RSV Production

BALB/c mice were obtained from The Jackson Laboratory and maintained at the Pontificia Universidad Católica de Chile animal facility (Santiago, Chile). All animal work was performed according to institutional guidelines. RSV serogroup A, strain 13018-B, is a clinical isolate provided by the Public Health Institute of Chile. Sequence comparison analyses reveal that this clinical strain is 96% identical to the standard RSV long strain (Fig. S5). RSV was propagated over iHeP-2 cells, as described in *SI Methods*. RSV preparations were routinely evaluated for lipopolysaccharide and mycoplasma contamination. Re- combinant production of RSV proteins was performed as described in *SI Methods*.

#### Generation of BCG Expressing RSV Proteins and Preparation of Vaccine Doses

BCG strains expressing the N or M2 proteins (BCG-N and BCG-M2, respectively) were generated as described in *SI Methods*. Expression of N or M2 proteins by BCG strains was assessed by Western blot analysis using rabbit antiserum against N or M2 protein, respectively. Vaccine doses of BCG-N, BCG-M2, or nonrecombinant BCG were prepared as described in *SI Methods*. BCG-OVA was generated as described previously (56).

#### Mouse Immunization and RSV Challenge

Four- to 6-week-old BALB/c mice (5–8 animals per group) received a subdermal injection with $1 \times 10^7$ pfu of WT-BCG, BCG-N, or BCG-M2 in the right dorsal flank. As controls, unimmunized mice or mice immunized with $1 \times 10^7$ pfu of UV-inactivated RSV infected with RSV in each experiment. At 7, 14, and 21 days after vaccination, serum samples were obtained from the tails of mice, and anti-N or anti-M2 antibodies (IgG) were detected by ELISA using 500 ng/well recombinant N or M2 proteins and serial dilutions of mouse sera. Twenty-one days after vaccination, mice were anesthetized with 150 µL of a 0.8% ketamine-0.1% xylazine solution in PBS and challenged intranasally with $1 \times 10^7$ pfu of RSV in 75-µL inoculums. Body weight was determined daily after vaccination and for 4 days after infection.

#### FACS Analyses of BAL Cells

After 4 days of infection, mice were terminally anesthetized, and lungs were inflated through the trachea 3 times with PBS. Recovered cells were stained with trypan blue and counted with a Neubauer chamber. A total of 200 µL was spun onto glass slides, air dried, and stained with May-Grünwald and Giemsa (Merck). Visual quantitation of neutrophils was performed in 6 random fields per sample on an Olympus BH-2 light microscope at 40× magnification. BALs were centrifuged at 300 × g for 5 min, resuspended in 100 µL of PBS, and stained with 0.1 µL of anti-CD11b-FITC and GR-1 (Ly-6-G)-APC (BD Pharmingen) for 30 min on ice. Data acquisition was performed on a FACSCalibur cytometer (BD Biosciences) and analyzed by using WinMDI 2.8 software (The Scripps Research Institute, La Jolla, CA; http://facs.scripps.edu/help/html/ read1plt.html).

#### Lung Histopathology

Lungs of control and infected mice were removed, and the right upper lobes were frozen in Tissue Freezing Medium (Jung) at –80 °C. Five-micrometer slices were prepared on a Leica CM 1510 S cryostat and stained.
with hematogenous/echoxen and evaluated for HPS as described in SI Methods. RSV detection in lung tissues was performed by immunohistochemistry and immuno- fluorescence, as described in SI Methods. Eosinophil infiltration was detected in 5-μm lung sections using the EoProbe staining kit according to the manufacturer’s instructions (BioFX Laboratories) and was analyzed on a fluorescence microscope (Olympus).

Cytokine Secretion by RSV-Specific T Cells. Spleen cells from unimmunized or mice immunized with WT-BCG, BCG-M2, BCG-N, or UV-BSV were obtained as described in SI Methods and incubated with 10 μg/ml of either recombinant protein N or M2. Recombinant proteins were produced as described in SI Methods. After 5 days of incubation, cytokine secretion was determined on supernatants by sandwich ELISA as described previously (57). Cytokine secretion was expressed as fold increase relative to unstimulated cells (treated only with PBS). CD69 expression and IFN-γ secretion by T cells were evaluated by flow cytometry, as described in SI Methods.

Adaptive Transfers of RSV-Specific T Cells to Naïve Mice. Spleen and lymph node cells from unimmunized mice or mice immunized with WT-BCG or BCG-N were cultured in the presence of HPS protein as described above. After 5 days, CD4+ and CD8+ cells were purified with CD4+ or CD8+ MACS T cell isolation kits according to the manufacturer’s instructions (Miltenyi Biotec). A total of 10^5 purified CD4+, CD8+, or a 1:1 mixture of CD4+ and CD8+ T cells were injected intravenously into syngeneic recipient mice. Recipient mice were challenged with 1 × 10^7 pfu of RSV 24 h later. Body weight was scored daily during the 5 days after infection, and BALs were analyzed for the presence of GR1+ and CD11b+ cells at days 5.

ACKNOWLEDGMENTS. We thank Dr. M. Ferré (Pontificia Universidad Católica de Chile, Santiago, Chile) for providing the RSV isolate, Dr. G. Tapia for help with CAT scan analyses, and J. P. Zúñiga and P. Bustos for technical assistance. This work was supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, and Ministerio de Educación y Ciencia (FIS2005-06508/BIOMED, FIS2006-14615/BIO). M.G. is recipient of a Ramón y Cajal fellowship (MEC). This study was supported by Grants P04/030-F. P.A.G. and H.E.T. are Comisión Nacional de Investigación Científica y Tecnológica fellows.
RSV Gene Cloning and Protein Production. RSV RNA was purified from RSV-infected HEp-2 cells by using TriZol reagent according to the manufacturer’s instructions (Invitrogen). RSV RNA was reverse transcribed to cDNA using ImProm Reverse II system kit (Promega). N and M2 genes were PCR amplified using the primers Fwd: 5’-CAT GAA TTC ATG GCT TCA AAG CTC TAC ATC ATT AT-3’ and Rev: 5’-CAT ATG GAA TTC TCA AAG CTC TAC ATC ATT AT-3’ for the N gene, and Fwd: 5’-CAT ATG GAA TTC TCA CGA AGG AAT CCT TG-3’ and Rev: 5’-GGA TCC AAG CTT TCA AGT AGT TG-3’ for the M2 gene. PCR amplification was performed using 2 ng/mL cDNA, 1 µM of each primer, and 20 units/mL native Pfx DNA polymerase (Invitrogen), using standard PCR amplification cycles. PCR products were gel purified and cloned into pCR-BluntII-TOPO cloning plasmid according to the manufacturer’s instructions (Invitrogen). The N or M2 gene was released from pCR-BluntII-TOPO by digestion with XhoI and BamHI and ligated into XhoI and BamHI-digested pET15b (Novagen) by using T4 DNA ligase (New England Biolabs). To produce recombinant N or M2 protein, Escherichia coli BL21 DE3 was electroporated with either pET15b-N or pET15b-M2 and grown on LB liquid media supplemented with 25 µg/mL carbenicillin (Merck) and 1 mM of isopropyl-β-D-thiogalactopyranoside (Sigma–Aldrich) until reaching OD_{600nm} equal to 0.5. Bacterial cells were recovered by centrifugation on a Beckman Centrifuge (Model J2–21; Beckman Coulter Inc.) at 7,000 × g for 15 min, and bacterial pellets were purified by sonication. Recombinant N and M2 proteins were purified by binding to Ni-NTA agarose (Invitrogen) and eluted with 20 mM of imidazol (Merck). Small aliquots of each purified protein were lysed by sonication. Recombinant N and M2 proteins were purified and cloned into pCR-BluntII-TOPO cloning plasmid according to the manufacturer’s instructions (Invitrogen). The N or M2 gene was released from pCR-BluntII-TOPO by digestion with XhoI and BamHI and ligated into XhoI and BamHI-digested pET15b (Novagen) by using T4 DNA ligase (New England Biolabs). To produce recombinant N or M2 protein, Escherichia coli BL21 DE3 was electroporated with either pET15b-N or pET15b-M2 and grown on LB liquid media supplemented with 25 µg/mL carbenicillin (Merck) and 1 mM of isopropyl-β-D-thiogalactopyranoside (Sigma–Aldrich) until reaching OD_{600nm} equal to 0.5. Bacterial cells were recovered by centrifugation on a Beckman Centrifuge (Model J2–21; Beckman Coulter Inc.) at 7,000 × g for 15 min, and bacterial pellets were purified by sonication. Recombinant N and M2 proteins were purified by binding to Ni-NTA agarose (Invitrogen) and eluted with 20 mM of imidazol (Merck). Small aliquots of each purified protein were stored at −80 °C until their use.

To generate BCG strains expressing either N or M2 proteins, the N or M2 genes were released from pCR-BluntII-TOPO by digestion with HindIII and EcoRI at 37 °C and ligated into HindIII and EcoRI-digested pMV361 (1) by using T4 DNA ligase (New England Biolabs). The BCG Danish strain was transformed with each of the individual recombinant plasmids by electroporation, and colonies were selected on 7H10 agar supplemented with 1× OADC (Difco), 0.05% Tween 80, 5% glycerol, and 20 µg/mL kanamycin. Expression of N or M2 proteins by BCG strains was assessed by Western blot analysis using rabbit antisera against N or M2 proteins, respectively. Vaccine doses of BCG-N, BCG-M2, or nonrecombinant BCG were prepared by growing bacteria on liquid media until reaching OD_{600} equal to 0.8, washed 3 times with 0.02% PBS-Tween 80, and frozen at −80 °C with glycerol 20% until their use.

Computed Axial Tomography. Computed axial tomography (CAT) scan was performed on BCG-M2-immunized and control mice infected with RSV. Uninfected mice were included as controls. Before CAT scans, mice were anesthetized with an 0.8% ketamine-0.1% xylazine solution in PBS and analyzed by using a Line Speed Ultra General Electric Scanner at the Hospital Clínico de Pontificia Universidad Católica de Chile. Slides of 0.625 mm thick were obtained in axial mode, at 80 kV and 40 mA.

Lung Histopathology. Lungs of control and infected mice were removed, and the right upper lobes were frozen in Tissue Freezing Medium (Jun) at −80°C. Slices of 5 µm were prepared on a Leica CM 1510 S cryostat and stained with hematoxylin/eosin. At least 6 random fields per sample were blind scored for histopathology by 3 independent observers using the following criteria: 0, no cell infiltration; 1, minimal cell infiltration; 2, slight cell infiltration; 3, moderate cell infiltration; and 4, severe cell infiltration. Images were captured on an Olympus BX51 light microscope at 40× magnification. For immunohistochemistry assays, the right middle lung lobe was fixed on 3% paraformaldehyde in TBS (0.025 M Tris base, 0.137 M NaCl, and 0.27 mM KCl) for 48 h at 4 °C. Tissue was then dehydrated and embedded in paraffin. Sections of 5 µm were mounted on glass, deparaffinized with xylene, rehydrated, and quenched for endogenous peroxidase using a solution of 10% H2O2 in TBS for 30 min. Tissues were blocked with 5% milk in TBS and incubated with 1:100 dilutions of HRP-conjugated goat anti-RSV (USBiologicals) at 4 °C overnight. After 6 washes with 0.5% milk/TBS, 80 µL of DAB substrate (0.06% 3,3’-diaminobenzidine tetrahydrochloride in buffer Tris, pH 7.6; Sigma–Aldrich) was added to each section and incubated for 15 min. Hematoxylin staining was used to identify nuclei, and samples were analyzed by using an Olympus BX51 light microscope at 100× magnification.

For immunofluorescence assays, right upper lobe lungs from control and infected mice were frozen in Tissue Freezing Medium (Jun) at −80 °C. Slices of 5 µm were cut on a Leica CM 1510 S cryostat, fixed, and permeabilized in 70% ethanol for 2 h at −20 °C. Then tissue sections were changed to 100% ethanol for 30 min and dried for another 30 min at room temperature. Before the staining, lung sections were hydrated starting with 95% ethanol for 30 min, then transferred to 75% ethanol for 5 min, transferred to 0.4% Triton X-100 in PBS for 5 min, and then rinsed twice in PBS. Sections were incubated in blocking solution (5 mM EDTA, 1% fish gelatin, 2% horse serum, and 1% essentially Ig-free BSA) for at least 30 min at room temperature and then incubated overnight at 4 °C with a biotin-conjugated rabbit polyclonal anti-RSV, diluted 1:200 in blocking solution (USBiologicals). Sections were then incubated with FITC-conjugated streptavidin (1:300) for 1 h at room temperature, followed by 4 washes in PBS. Fluorescence counterstaining was obtained by using a Cy3-conjugated anti-λ Willebrand factor antibody (1:200). Coverslips were mounted and examined in a Bio-Rad Radiance 2000 Laser Scanning Confocal Microscope. Specific immunoreactivity was confirmed by replacing the primary antibody with a nonimmune polyclonal reagent or by staining with FITC-conjugated streptavidin without primary antibody. To evaluate the presence of RSV in lung tissues, serial Z-sections were obtained (0.8 µm each section) and integrated by using Image J (National Institutes of Health) and Adobe Photoshop (Adobe Systems) programs.

Detection of CD69 Expression and IFN-γ Secretion by T Cells. Spleens were obtained from unimmunized or mice immunized with WT-BCG, BCG-M2, BCG-N, or UV-RSV; red blood cells were lysed; and 5 × 106 cells/mL were cultured in 6-well plates in RPMI-1640 (GIBCO) containing 5% FCS (Biological Indus-
tries), 1 mM of nonessential amino acids, 2 mM of glutamine, 1 mM of pyruvate, 100 units/mL penicillin G, 100 μg/mL streptomycin (GIBCO), and 50 μg/mL gentamicin (Merck) and incubated with 10 μg/mL of either recombinant protein N or M2. After 5 days of incubation, cytokine secretion was determined on supernatants by sandwich ELISA as described previously (2). To detect expression of the early activation marker CD69 on T cells, cells obtained from spleen were stimulated with 10 μg/mL of either proteins N or M2. After 72 h of incubation, 1 × 10⁶ cells were resuspended in 100 μL of PBS and stained with anti-CD4-APC (clone RM4-5), anti-CD8a-FITC (clone 53-6.7), and anti-CD69-PE (clone H1.2F3) for 1 h on ice, washed with PBS, and analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences). For intracellular cytokine staining, T cells were treated for 5 h with 10 μM Brefeldin A (Invitrogen), permeabilized with PBS-saponin 0.5%-BSA 3%, stained with an FITC-labeled anti-IFN-γ (clone XMG1.2), and washed with PBS-BSA 3%. Unstimulated cells were included as negative controls in all experiments. Cells were analyzed by flow cytometry on a FACSCalibur flow cytometer (BD Biosciences), and all antibodies were obtained from BD PharMingen.

**Real-Time PCR Detection of RSV in Lungs.** Total RNA was obtained from lungs by using TriZol Reagent (Invitrogen), as suggested by the manufacturer. Total RNA was reverse transcribed to cDNA by the use of Improm-II Reverse transcription system (Promega). Then, N and β-actin genes were detected by real-time PCR using Brilliant QPCR Master Mix (Stratagene) on an Mx3000P thermocycler (Stratagene). Data are expressed as copy numbers of N gene per 5,000 copies of β-actin. Primers used for RSV N gene detection were Fwd: 5’-GAG ACA GCA GCA TTG ACA CTC CT-3’ and Rev: 5’-CGA TGT GTT GTT ACA TCC ACT-3’. Detection of β-actin was used as a housekeeping reference gene with primers Fwd: 5’-AGG CAT CCT GAC CCT GAA GTA C-3’ and Rev: 5’-TCT TCA TGA GGT AGT CTG TCA G-3’.


Immunization with BCG expressing RSV antigens prevents lung pathology after RSV infection. Unimmunized mice and mice immunized with BCG-M2 were intranasally challenged with RSV, and lung pathology was evaluated after 3 days by CAT. Data shown are 2 representative slides of thoraces from unimmunized and BCG-M2-immunized animals after RSV challenge. Uninfected animals were included as a control. Arrowheads indicate pneumonia inflammatory foci.
Fig. S2. Immunization with BCG expressing RSV antigens reduces eosinophil recruitment to the lungs. Lung sections from unimmunized and immunized mice were stained as described in Methods to detect eosinophil infiltration. Nuclei were counterstained with Hoechst 33342 (Upper) and eosinophils were stained red (Lower), as described in Methods. BCG-M2-immunized and BCG-N-immunized animals showed significantly reduced levels of eosinophil recruitment to lungs upon RSV infection.
Fig. S3. Immunization with BCG-N fails to protect RAG$^{-/-}$ mice against RSV infection. RAG-deficient BALB/c mice (RAG$^{-/-}$) were immunized with $1 \times 10^8$ cfu of BCG-N and challenged with $1 \times 10^7$ pfu of RSV after 21 days. Uninfected and unimmunized animals were included as controls. (A) Body weight loss after RSV infection. BCG-N immunization did not confer protection against RSV infection in RAG$^{-/-}$ mice. (B) Percentage of neutrophils on BALs from RAG$^{-/-}$ mice. BAL cells were obtained as described in Methods and stained with an APC-labeled anti-GR1 (Ly-6G) antibody and analyzed by flow cytometry.
Immunization with attenuated Salmonella expressing RSV antigens fails to confer protection against RSV infection. BALB/c mice were immunized with $1 \times 10^4$ cfu of an attenuated strain of Salmonella typhimurium (lacking Pathogenicity island 2), which expresses the RSV-M2 protein (STM-SPI2-M2). As controls, groups of mice immunized with parental STM-SPI2 (nonrecombinant Salmonella), uninfected mice, and unimmunized mice were included. (A) After 21 days of immunization, mice were challenged with $1 \times 10^7$ pfu of RSV, and body weight loss was recorded for 4 days. (B) Percentage of neutrophils on BALs. BAL cells were obtained as described in Methods and stained with an FITC-labeled anti-CD11b antibody and analyzed by flow cytometry. Data are expressed as fold-increase values relative to uninfected mice and are means of at least 3 independent experiments.
Comparative sequence analysis for RSV strains 13018-8 and Long. RSV 13018-8 N (A) and M2 (B) genes were compared to RSV long strain (National Center for Biotechnology Information accession number AY911262), showing that more than 96% of nucleotide sequence is shared between both strains.
Movie S1. Computed tomography to evaluate lung infiltration after RSV infection. Unimmunized mouse 3 days after RSV infection. Arrowheads indicate pneumonia inflammatory foci.

Movie S1 (MOV)
Movie S2. Computed tomography to evaluate lung infiltration after RSV infection. Uninfected mouse.

Movie S2 (MOV)
Movie S3. Computed tomography to evaluate lung infiltration after RSV infection. Bacillus Calmette–Guérin-M2-immunized mouse 3 days after RSV infection.

Movie S3 (MOV)